Leydig cell function in patients with testicular cancer during and after chemotherapy

Publisher Website
Google Scholar
Abstract
In 2 groups of patients with disseminated testicular carcinoma the effect of combination chemotherapy on the pituitary-gonadal axis was evaluated, after unilateral orchiectomy. The two groups comprised 15 patients without hCG[human chorionic gonadotropin]-producing metastases (group A), and 14 patients with hCG-producing metastases (group B). Seven patients who had received no chemotherapy were studied 1 yr after unilateral orchiectomy as a control group (group C). In group A, serum levels of testosterone and estradiol increased during chrmotherapy, as did the levels of LH [luteinizing hormone] and FSH. The serum LH and FSH response to LHRH was increased following chemotherapy, whereas the serum testosterone increase after hCG stimulation remained unchanged. A rise of 316% in SHBG [sex hormone binding globulin] binding capacity was found after chemotherapy. This presumably accounted for the evaluated steroid levels in the presence of high gonadotropin levels, but unaltered Leydig cell response. The evaluated serum levels of testosterone and estradiol and the suppressed serum FSH levels normalized during disappearance of ectopic hCG production in group B patients. Leydig cell refractoriness to hCG and the FSH response to LHRH also reverted to normal. After chemotherapy, FSH, but not LH levels, exceeded those of group C patients, presumably as a result of the azoospermia induced by chemotherapy. The hormonal changes associated with chemotherapy are best explained by an increase in serum binding proteins, notably SHBG.